{ "instance": { "gblx20220331b_10k.htm": { "axisCustom": 0, "axisStandard": 30, "contextCount": 257, "dts": { "calculationLink": { "local": [ "gblx-20220331_cal.xml" ] }, "definitionLink": { "local": [ "gblx-20220331_def.xml" ] }, "inline": { "local": [ "gblx20220331b_10k.htm" ] }, "labelLink": { "local": [ "gblx-20220331_lab.xml" ] }, "presentationLink": { "local": [ "gblx-20220331_pre.xml" ] }, "schema": { "local": [ "gblx-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 590, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 45, "http://gbsciences.com/20220331": 8, "http://xbrl.sec.gov/dei/2022": 6, "total": 59 }, "keyCustom": 103, "keyStandard": 292, "memberCustom": 62, "memberStandard": 28, "nsprefix": "gblx", "nsuri": "http://gbsciences.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://gbsciences.com/20220331/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Discontinued Operations", "role": "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "shortName": "Note 4 - Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Notes Payable and Line of Credit", "role": "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "shortName": "Note 5 - Notes Payable and Line of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "gblx:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Convertible Notes", "role": "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "shortName": "Note 6 - Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "gblx:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Property and Equipment", "role": "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment", "shortName": "Note 7 - Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Income Taxes", "role": "http://gbsciences.com/20220331/role/statement-note-8-income-taxes", "shortName": "Note 8 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Capital Transactions", "role": "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "shortName": "Note 9 - Capital Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Employee Benefit Plan", "role": "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "shortName": "Note 10 - Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 11 - Commitments and Contingencies", "role": "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "shortName": "Note 11 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 12 - Related Party Transactions", "role": "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "shortName": "Note 12 - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31_SubsidiarySaleOfStockAxis-NevadaSubsidiariesMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 13 - Sale of Membership Interests in Nevada Subsidiaries", "role": "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "shortName": "Note 13 - Sale of Membership Interests in Nevada Subsidiaries", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31_SubsidiarySaleOfStockAxis-NevadaSubsidiariesMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "role": "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 14 - Concentrations", "role": "http://gbsciences.com/20220331/role/statement-note-14-concentrations", "shortName": "Note 14 - Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 15 - Subsequent Events", "role": "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "shortName": "Note 15 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 4 - Discontinued Operations (Tables)", "role": "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables", "shortName": "Note 4 - Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 5 - Notes Payable and Line of Credit (Tables)", "role": "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-tables", "shortName": "Note 5 - Notes Payable and Line of Credit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 8 - Income Taxes (Tables)", "role": "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-tables", "shortName": "Note 8 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 9 - Capital Transactions (Tables)", "role": "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-tables", "shortName": "Note 9 - Capital Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 10 - Employee Benefit Plan (Tables)", "role": "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-tables", "shortName": "Note 10 - Employee Benefit Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "gblx:ScheduleOfDeconsolidationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 13 - Sale of Membership Interests in Nevada Subsidiaries (Tables)", "role": "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-tables", "shortName": "Note 13 - Sale of Membership Interests in Nevada Subsidiaries (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "gblx:ScheduleOfDeconsolidationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2019-08-15", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 1 - Background and Nature of Operations (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "shortName": "Note 1 - Background and Nature of Operations (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2019-08-15", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 2 - Going Concern (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual", "shortName": "Note 2 - Going Concern (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "lang": null, "name": "gblx:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2021-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 4 - Discontinued Operations (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "shortName": "Note 4 - Discontinued Operations (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "i", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2019-11-27_CreditFacilityAxis-LineOfCreditMember", "decimals": "2", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 4 - Discontinued Operations - Discontinued Operations (Details)", "role": "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "shortName": "Note 4 - Discontinued Operations - Discontinued Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31_StatementOperatingActivitiesSegmentAxis-SegmentContinuingOperationsMember", "decimals": "INF", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2021-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 4 - Discontinued Operations - Schedule of Inventory (Details)", "role": "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details", "shortName": "Note 4 - Discontinued Operations - Schedule of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31_DisposalGroupClassificationAxis-DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember", "decimals": "INF", "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31_StatementOperatingActivitiesSegmentAxis-SegmentDiscontinuedOperationsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 4 - Discontinued Operations - Lease Costs Recorded in the Company's Financial Statements (Details)", "role": "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details", "shortName": "Note 4 - Discontinued Operations - Lease Costs Recorded in the Company's Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31_StatementOperatingActivitiesSegmentAxis-SegmentDiscontinuedOperationsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 5 - Notes Payable and Line of Credit (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "shortName": "Note 5 - Notes Payable and Line of Credit (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2020-12-29_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TheJuly24NoteMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-TecoSubsidiariesMember", "decimals": "INF", "lang": null, "name": "us-gaap:NotesReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31_LongtermDebtTypeAxis-PromissoryNoteMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 5 - Notes Payable and Line of Credit - Summary of Notes and Convertible Notes Payable (Details)", "role": "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "shortName": "Note 5 - Notes Payable and Line of Credit - Summary of Notes and Convertible Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31_LongtermDebtTypeAxis-PromissoryNoteMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "gblx:ClassOfWarrantOrRightIssuedDuringPeriod", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 6 - Convertible Notes (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "shortName": "Note 6 - Convertible Notes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "gblx:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2020-07-14_LitigationCaseAxis-RepaymentOfIliadNoteMember_LitigationStatusAxis-JudicialRulingMember", "decimals": "2", "lang": null, "name": "gblx:DebtInstrumentDebtDefaultInterestRatePenalty", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 7 - Property and Equipment (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment-details-textual", "shortName": "Note 7 - Property and Equipment (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations", "role": "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 8 - Income Taxes (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual", "shortName": "Note 8 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 8 - Income Taxes - Reconciliation of Effective Income Tax Expense (Benefit) (Details)", "role": "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details", "shortName": "Note 8 - Income Taxes - Reconciliation of Effective Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "role": "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details", "shortName": "Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromWarrantExercises", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 9 - Capital Transactions (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "shortName": "Note 9 - Capital Transactions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2020-04-01_2021-03-31_TitleOfIndividualAxis-ScientistAndResearcherMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 9 - Capital Transactions - Warrant Activity (Details)", "role": "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details", "shortName": "Note 9 - Capital Transactions - Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2020-04-01_2021-03-31_RangeAxis-MinimumMember", "decimals": "INF", "lang": null, "name": "gblx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "gblx:ClassOfWarrantOrRightExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 10 - Employee Benefit Plan (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "shortName": "Note 10 - Employee Benefit Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2020-04-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 10 - Employee Benefit Plan - Assumptions (Details)", "role": "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details", "shortName": "Note 10 - Employee Benefit Plan - Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2020-04-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2021-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 10 - Employee Benefit Plan - Option Activity (Details)", "role": "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "shortName": "Note 10 - Employee Benefit Plan - Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "gblx:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2020-07-14_2020-07-14_LitigationCaseAxis-RepaymentOfIliadNoteMember_LitigationStatusAxis-JudicialRulingMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "shortName": "Note 11 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2020-04-22_2020-04-22_LitigationCaseAxis-PaymentOfServicesProvidedByContractorMember_LitigationStatusAxis-PendingLitigationMember", "decimals": "INF", "lang": null, "name": "us-gaap:LossContingencyDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 12 - Related Party Transactions (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual", "shortName": "Note 12 - Related Party Transactions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2020-11-16_RelatedPartyTransactionsByRelatedPartyAxis-LeslieBocskorMember", "decimals": "INF", "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Changes in Stockholders' Equity/(Deficit)", "role": "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "shortName": "Consolidated Statements of Changes in Stockholders' Equity/(Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NotesReduction", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 13 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "shortName": "Note 13 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-12-31_2021-12-31_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-GBSciencesNopahLLCMember", "decimals": "-3", "lang": null, "name": "us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 13 - Sale of Membership Interests in Nevada Subsidiaries - Gain on Deconsolidation (Details)", "role": "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details", "shortName": "Note 13 - Sale of Membership Interests in Nevada Subsidiaries - Gain on Deconsolidation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "gblx:ScheduleOfDeconsolidationTableTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-12-31_2021-12-31_OwnershipAxis-NevadaSubsidiariesMember", "decimals": "INF", "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 14 - Concentrations (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-14-concentrations-details-textual", "shortName": "Note 14 - Concentrations (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "i_2021-07-18_ClassOfWarrantOrRightAxis-WarrantsIssuedToInvestorsInPrivatePlacementsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 15 - Subsequent Events (Details Textual)", "role": "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "shortName": "Note 15 - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2022-05-09_2022-05-09_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "lang": null, "name": "gblx:SaleOfUnitsMaximumUnitsAllowedInPrivatePlacement", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "role": "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Background and Nature of Operations", "role": "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "shortName": "Note 1 - Background and Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Going Concern", "role": "http://gbsciences.com/20220331/role/statement-note-2-going-concern", "shortName": "Note 2 - Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gblx20220331b_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 98, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-document-and-entity-information", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-tables", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details-parentheticals", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-tables", "http://gbsciences.com/20220331/role/statement-note-14-concentrations", "http://gbsciences.com/20220331/role/statement-note-14-concentrations-details-textual", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-2-going-concern", "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-tables", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment-details-textual", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-tables", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-tables", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details", "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r569" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-document-and-entity-information", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-tables", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details-parentheticals", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-tables", "http://gbsciences.com/20220331/role/statement-note-14-concentrations", "http://gbsciences.com/20220331/role/statement-note-14-concentrations-details-textual", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-2-going-concern", "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-tables", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment-details-textual", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-tables", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-tables", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details", "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "gblx_AccountsPayableDueToAffiliateOfThePurchaserMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents accounts payable to affiliate of purchaser.", "label": "Accounts Payable Due to Affiliate of the Purchaser [Member]" } } }, "localname": "AccountsPayableDueToAffiliateOfThePurchaserMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "gblx_AccruedInterestCapitalizedInConvertibleNotePrincipal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of accrued interest capitalized in convertible note principal during the period.", "label": "gblx_AccruedInterestCapitalizedInConvertibleNotePrincipal", "verboseLabel": "Accrued interest capitalized in convertible note principal" } } }, "localname": "AccruedInterestCapitalizedInConvertibleNotePrincipal", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "gblx_AccruedLiabilitesForgiven": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of accrued liabilities forgiven during the period.", "label": "Accrued liabilities forgiven in connection with Wellcana Note settlement" } } }, "localname": "AccruedLiabilitesForgiven", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "gblx_AccruedManagementFeesPayablesReduction": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details": { "order": 0.0, "parentTag": "gblx_DeconsolidationEntitysInterestNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of accrued management fee payables reduced (or transferred to another entity) in noncash investing or financing transactions.", "label": "Extinguishment of accrued management fees due to purchaser", "verboseLabel": "Extinguishment of accrued management fees payable to purchaser of Nevada Subsidiaries" } } }, "localname": "AccruedManagementFeesPayablesReduction", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details" ], "xbrltype": "monetaryItemType" }, "gblx_BrokerageFeesForIssuanceOfCommonStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for brokerage fees for issuance of common stock and warrants during the current period.", "label": "gblx_BrokerageFeesForIssuanceOfCommonStockAndWarrants", "terseLabel": "Brokerage Fees for Issuance of Common Stock and Warrants" } } }, "localname": "BrokerageFeesForIssuanceOfCommonStockAndWarrants", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_ClassOfWarrantOrRightCancelledDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights cancelled during period.", "label": "gblx_ClassOfWarrantOrRightCancelledDuringPeriod", "negatedLabel": "Warrants expired/cancelled (in shares)" } } }, "localname": "ClassOfWarrantOrRightCancelledDuringPeriod", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "gblx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share of warrants or rights cancelled during period.", "label": "Warrants expired/cancelled, exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "gblx_ClassOfWarrantOrRightExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercised during period.", "label": "gblx_ClassOfWarrantOrRightExercisedDuringPeriod", "negatedLabel": "Warrants exercised (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "gblx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share of warrants or rights exercised during period.", "label": "Warrants exercised, exercise price (in dollars per share)", "terseLabel": "Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "gblx_ClassOfWarrantOrRightExercisedDuringPeriodIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of warrant or right exercised during the period.", "label": "gblx_ClassOfWarrantOrRightExercisedDuringPeriodIntrinsicValue", "terseLabel": "Class of Warrant or Right, Exercised During Period, Intrinsic Value" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriodIntrinsicValue", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_ClassOfWarrantOrRightExercisesInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercised in the period.", "label": "gblx_ClassOfWarrantOrRightExercisesInPeriod", "terseLabel": "Class of Warrant or Right, Exercises in Period (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisesInPeriod", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "sharesItemType" }, "gblx_ClassOfWarrantOrRightExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense for the issuance of warrants or rights.", "label": "gblx_ClassOfWarrantOrRightExpense", "terseLabel": "Class of Warrant or Right, Expense" } } }, "localname": "ClassOfWarrantOrRightExpense", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_ClassOfWarrantOrRightExtensionPeriodOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The extension period of securities into which the class of warrant or right may be converted. For example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "gblx_ClassOfWarrantOrRightExtensionPeriodOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Extension Period of Securities Called by Warrants or Rights (Year)" } } }, "localname": "ClassOfWarrantOrRightExtensionPeriodOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "durationItemType" }, "gblx_ClassOfWarrantOrRightIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights issued in the period.", "label": "gblx_ClassOfWarrantOrRightIssued", "terseLabel": "Class of Warrant or Right, Issued (in shares)" } } }, "localname": "ClassOfWarrantOrRightIssued", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "sharesItemType" }, "gblx_ClassOfWarrantOrRightIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights issued during period.", "label": "Warrants issued (in shares)", "terseLabel": "Class of Warrant or Right, Issued During Period (in shares)" } } }, "localname": "ClassOfWarrantOrRightIssuedDuringPeriod", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "gblx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share of warrants or rights issued during period.", "label": "Warrants issued, exercise price (in dollars per share)", "terseLabel": "Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "gblx_ClassOfWarrantOrRightIssuedDuringPeriodFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrant or right issued during the period.", "label": "gblx_ClassOfWarrantOrRightIssuedDuringPeriodFairValue", "terseLabel": "Class of Warrant or Right, Issued During Period, Fair Value" } } }, "localname": "ClassOfWarrantOrRightIssuedDuringPeriodFairValue", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_CompensationWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents compensation warrants.", "label": "Compensation Warrant [Member]" } } }, "localname": "CompensationWarrantMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "domainItemType" }, "gblx_CompensationWarrantsIssuedToBrokersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the compensation warrants issued to brokers.", "label": "Compensation Warrants Issued to Brokers [Member]" } } }, "localname": "CompensationWarrantsIssuedToBrokersMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_ConvertibleDebtTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entire disclosure for convertible debt.", "label": "Convertible Debt [Text Block]" } } }, "localname": "ConvertibleDebtTextBlock", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes" ], "xbrltype": "textBlockItemType" }, "gblx_ConvertibleWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to convertible warrants.", "label": "Convertible Warrant [Member]" } } }, "localname": "ConvertibleWarrantMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_CultivationLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the cultivation license found within the Nevada Medical Marijuana Production License Agreement.", "label": "Cultivation License [Member]" } } }, "localname": "CultivationLicenseMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "gblx_CurrentEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to current employees.", "label": "Current Employees [Member]" } } }, "localname": "CurrentEmployeesMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_DebtDefaultPenalty": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defaulting on debt.", "label": "gblx_DebtDefaultPenalty", "negatedLabel": "Debt default penalty", "terseLabel": "Debt Default Penalty" } } }, "localname": "DebtDefaultPenalty", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentConvertibleDiscountFairValueOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount if discount applied to a convertible debt instrument based on the fair value of the warrants attached to the note.", "label": "gblx_DebtInstrumentConvertibleDiscountFairValueOfWarrants", "terseLabel": "Debt Instrument, Convertible, Discount, Fair Value of Warrants" } } }, "localname": "DebtInstrumentConvertibleDiscountFairValueOfWarrants", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentConvertibleNumberOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants that the holder of the debt instrument would receive if the debt was converted to warrants.", "label": "gblx_DebtInstrumentConvertibleNumberOfWarrants", "terseLabel": "Debt Instrument, Convertible, Number of Warrants" } } }, "localname": "DebtInstrumentConvertibleNumberOfWarrants", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "integerItemType" }, "gblx_DebtInstrumentDebtDefaultIncreaseInPrincipalAmountPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the increase to the debt instrument principal amount resulting from defaulting on the debt instrument.", "label": "gblx_DebtInstrumentDebtDefaultIncreaseInPrincipalAmountPercent", "terseLabel": "Debt Instrument, Debt Default, Increase in Principal Amount, Percent" } } }, "localname": "DebtInstrumentDebtDefaultIncreaseInPrincipalAmountPercent", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "percentItemType" }, "gblx_DebtInstrumentDebtDefaultInterestExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of interest expense during the period for a debt instrument that has been defaulted.", "label": "gblx_DebtInstrumentDebtDefaultInterestExpense", "terseLabel": "Debt Instrument, Debt Default, Interest Expense" } } }, "localname": "DebtInstrumentDebtDefaultInterestExpense", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentDebtDefaultInterestRatePenalty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the interest rate penalty to be imposed in the case of defaulting on a debt instrument.", "label": "gblx_DebtInstrumentDebtDefaultInterestRatePenalty", "terseLabel": "Debt Instrument, Debt Default, Interest Rate Penalty" } } }, "localname": "DebtInstrumentDebtDefaultInterestRatePenalty", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "percentItemType" }, "gblx_DebtInstrumentDebtDefaultPrincipalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense incurred during the period due to the increase in principal amount owing on a debt instrument which has been defaulted.", "label": "gblx_DebtInstrumentDebtDefaultPrincipalExpense", "terseLabel": "Debt Instrument, Debt Default, Principal Expense" } } }, "localname": "DebtInstrumentDebtDefaultPrincipalExpense", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentExtendedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The extended amount of a debt instrument.", "label": "gblx_DebtInstrumentExtendedAmount", "terseLabel": "Debt Instrument, Extended Amount" } } }, "localname": "DebtInstrumentExtendedAmount", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentExtensionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The extension period of a debt instrument.", "label": "gblx_DebtInstrumentExtensionPeriod", "terseLabel": "Debt Instrument, Extension Period (Year)" } } }, "localname": "DebtInstrumentExtensionPeriod", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "durationItemType" }, "gblx_DebtInstrumentFaceAmountContinuingOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance, for debt instruments classified as continuing operations.", "label": "Face Value, long-term notes payable", "terseLabel": "Total short term notes and convertible notes payable classified as continuing operations" } } }, "localname": "DebtInstrumentFaceAmountContinuingOperations", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentFaceAmountDiscontinuedOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance, for debt instruments classified as discontinued operations.", "label": "gblx_DebtInstrumentFaceAmountDiscontinuedOperations", "negatedLabel": "Less: Notes payable classified as discontinued operations, face value" } } }, "localname": "DebtInstrumentFaceAmountDiscontinuedOperations", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentFaceAmountPerNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The face (par) amount of each note unit offered at time of issuance.", "label": "gblx_DebtInstrumentFaceAmountPerNote", "terseLabel": "Debt Instrument, Face Amount Per Note" } } }, "localname": "DebtInstrumentFaceAmountPerNote", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentForgivenessRatioOfNotesReceivableAmountReducedToTheDebtBalanceOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The ratio of the amount of reduction in the notes receivable to the balance of debt outstanding for forgiveness of the debt instrument.", "label": "gblx_DebtInstrumentForgivenessRatioOfNotesReceivableAmountReducedToTheDebtBalanceOutstanding", "terseLabel": "Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding" } } }, "localname": "DebtInstrumentForgivenessRatioOfNotesReceivableAmountReducedToTheDebtBalanceOutstanding", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "pureItemType" }, "gblx_DebtInstrumentInterestRateStatedPercentageAfterTermModification": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the modified agreement.", "label": "gblx_DebtInstrumentInterestRateStatedPercentageAfterTermModification", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage, After Term Modification" } } }, "localname": "DebtInstrumentInterestRateStatedPercentageAfterTermModification", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "percentItemType" }, "gblx_DebtInstrumentMonthlyPaymentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of monthly payments for outstanding debt instrument in accordance with agreement terms.", "label": "gblx_DebtInstrumentMonthlyPaymentAmount", "terseLabel": "Debt Instrument, Monthly Payment, Amount" } } }, "localname": "DebtInstrumentMonthlyPaymentAmount", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentPresentValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of a debt instrument after future cash amounts attributable to the debt instrument have been discounted to an earlier time.", "label": "gblx_DebtInstrumentPresentValue", "terseLabel": "Debt Instrument, Present Value" } } }, "localname": "DebtInstrumentPresentValue", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentPrincipalBalanceAfterReductionUponCloseOfAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount to which the principal balance of the debt instrument will be reduced upon the closing of a disposition.", "label": "gblx_DebtInstrumentPrincipalBalanceAfterReductionUponCloseOfAgreement", "terseLabel": "Debt Instrument, Principal Balance After Reduction Upon Close of Disposition" } } }, "localname": "DebtInstrumentPrincipalBalanceAfterReductionUponCloseOfAgreement", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentUnamortizedDiscountCurrentContinuingOperations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer, for debt instruments classified as continuing operations.", "label": "gblx_DebtInstrumentUnamortizedDiscountCurrentContinuingOperations", "negatedTerseLabel": "Total short term notes and convertible notes payable classified as continuing operations" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrentContinuingOperations", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "gblx_DebtInstrumentUnamortizedDiscountCurrentDiscontinuedOperations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer, classified as discontinued operations.", "label": "Less: Notes payable classified as discontinued operations, discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrentDiscontinuedOperations", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "gblx_DeconsolidationAssetsNet": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details": { "order": 1.0, "parentTag": "us-gaap_DeconsolidationGainOrLossAmount", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after liabilities, of entity's interest in assets after deconsolidation of subsidiary.", "label": "gblx_DeconsolidationAssetsNet", "totalLabel": "Net assets deconsolidated" } } }, "localname": "DeconsolidationAssetsNet", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details" ], "xbrltype": "monetaryItemType" }, "gblx_DeconsolidationCarryingAmountOfAssets": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details": { "order": 1.0, "parentTag": "gblx_DeconsolidationAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the carrying amount of entity's interest in assets after deconsolidation of subsidiary.", "label": "Carrying amount of assets" } } }, "localname": "DeconsolidationCarryingAmountOfAssets", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details" ], "xbrltype": "monetaryItemType" }, "gblx_DeconsolidationCarryingAmountOfLiabilities": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details": { "order": 0.0, "parentTag": "gblx_DeconsolidationAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the carrying amount of entity's interest in liabilities after deconsolidation of subsidiary.", "label": "gblx_DeconsolidationCarryingAmountOfLiabilities", "negatedLabel": "Carrying amount of liabilities" } } }, "localname": "DeconsolidationCarryingAmountOfLiabilities", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details" ], "xbrltype": "monetaryItemType" }, "gblx_DeconsolidationEntitysInterestNet": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details": { "order": 0.0, "parentTag": "us-gaap_DeconsolidationGainOrLossAmount", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the total amount of entity's interest after deconsolidation of subsidiary.", "label": "gblx_DeconsolidationEntitysInterestNet", "totalLabel": "Total consideration" } } }, "localname": "DeconsolidationEntitysInterestNet", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details" ], "xbrltype": "monetaryItemType" }, "gblx_DefaultPenatlyOnConvertibleNotePayable": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of default penalty on convertible note payable.", "label": "Debt default penalty" } } }, "localname": "DefaultPenatlyOnConvertibleNotePayable", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "gblx_DepreciationCapitalizedInInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense recognized in the current period which allocates the declining value of inventory over its useful life.", "label": "gblx_DepreciationCapitalizedInInventory", "verboseLabel": "Depreciation capitalized in inventory (discontinued operations)" } } }, "localname": "DepreciationCapitalizedInInventory", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "gblx_DepreciationCapitalizedToInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of depreciation capitalized to inventory during the period.", "label": "gblx_DepreciationCapitalizedToInventory", "terseLabel": "Depreciation, Capitalized to Inventory" } } }, "localname": "DepreciationCapitalizedToInventory", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_DurationQuarterlyPrincipalAndInterestPaymentsOnNoteReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measured in units, the number of the quarterly principal and interest payments payable to the Company on a note receivable.", "label": "gblx_DurationQuarterlyPrincipalAndInterestPaymentsOnNoteReceivable", "terseLabel": "Number of Quarterly Principal and Interest Payments on Note Receivable" } } }, "localname": "DurationQuarterlyPrincipalAndInterestPaymentsOnNoteReceivable", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "pureItemType" }, "gblx_EffectiveIncomeTaxRateReconciliationAdjustmentsToValuationOfDeferredTaxAssets": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to adjustments to valuation of deferred tax assets.", "label": "gblx_EffectiveIncomeTaxRateReconciliationAdjustmentsToValuationOfDeferredTaxAssets", "verboseLabel": "Adjustments to valuation of deferred tax assets" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAdjustmentsToValuationOfDeferredTaxAssets", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "gblx_EffectiveIncomeTaxRateReconciliationIrcSection280eAmount": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to IRC section 280E.", "label": "IRC Section 280E" } } }, "localname": "EffectiveIncomeTaxRateReconciliationIrcSection280eAmount", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "gblx_EffectiveIncomeTaxRateReconciliationTaxReturnTrueup": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents tax return true-up for effective income tax rate reconciliation.", "label": "Tax return true-up" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxReturnTrueup", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "gblx_EmployeesAndDirectorWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to employees and director warrants.", "label": "Employees and Director Warrants [Member]" } } }, "localname": "EmployeesAndDirectorWarrantsMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_EmployeesAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to employees and directors.", "label": "Employees and Directors [Member]" } } }, "localname": "EmployeesAndDirectorsMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_ExerciseOfWarrantsForStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the exercise of warrants.", "label": "Exercise of warrants for stock (in shares)", "terseLabel": "Exercise of Warrants for Stock, Shares (in shares)" } } }, "localname": "ExerciseOfWarrantsForStockShares", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "sharesItemType" }, "gblx_ExerciseOfWarrantsForStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of Exercise of warrants for stock, value, during the indicated time period.", "label": "Exercise of warrants for stock", "terseLabel": "Exercise of warrants for stock", "verboseLabel": "Issuance of shares upon exercise of compensation warrants" } } }, "localname": "ExerciseOfWarrantsForStockValue", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "monetaryItemType" }, "gblx_FinalPaymentPrincipalAndInterestPaymentsDueOnNoteReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of final payment of principal and interest payments due to the Company on the note receivable.", "label": "gblx_FinalPaymentPrincipalAndInterestPaymentsDueOnNoteReceivable", "terseLabel": "Final Payment, Principal and Interest Payments Due on Note Receivable" } } }, "localname": "FinalPaymentPrincipalAndInterestPaymentsDueOnNoteReceivable", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_FinitelivedIntangibleAssetsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of finite-lived intangible assets.", "label": "gblx_FinitelivedIntangibleAssetsNumber", "terseLabel": "Finite-Lived Intangible Assets, Number" } } }, "localname": "FinitelivedIntangibleAssetsNumber", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "gblx_FormerDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to former director.", "label": "Former Director [Member]" } } }, "localname": "FormerDirectorMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_GBSciencesInc2007AmendedStockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the GB Sciences, Inc. 2007 Amended Stock Option Plan.", "label": "GB Sciences, Inc. 2007 Amended Stock Option Plan [Member]" } } }, "localname": "GBSciencesInc2007AmendedStockOptionPlanMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual" ], "xbrltype": "domainItemType" }, "gblx_GBSciencesNevadaLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to GB Sciences, Nevada, LLC.", "label": "GB Sciences, Nevada, LLC [Member]" } } }, "localname": "GBSciencesNevadaLLCMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_GBSciencesNopahLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to GB Sciences Nopah, LLC.", "label": "GB Sciences Nopah, LLC [Member]" } } }, "localname": "GBSciencesNopahLLCMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "gblx_GainLossOnAmendmentToLineOfCredit": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain (loss) on the amendment to the line of credit.", "label": "Loss on modification of line of credit", "negatedLabel": "Loss on modification of line of credit", "terseLabel": "Gain (Loss) on Amendment to Line of Credit" } } }, "localname": "GainLossOnAmendmentToLineOfCredit", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_GainLossOnModificationOfNotesReceivable": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain (loss) on modification of notes receivable.", "label": "Loss on impairment of note receivable", "negatedLabel": "Loss on impairment of note receivable" } } }, "localname": "GainLossOnModificationOfNotesReceivable", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "gblx_GainLossOnSettlementOfAccountsPayable": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on settlement of accounts payable.", "label": "Gain on settlement of accounts payable", "negatedLabel": "Gain on settlement of accounts payable" } } }, "localname": "GainLossOnSettlementOfAccountsPayable", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "gblx_GbSciencesInc2018StockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the GB Sciences, Inc 2018 Stock Plan.", "label": "GB Sciences, Inc 2018 Stock Plan [Member]" } } }, "localname": "GbSciencesInc2018StockPlanMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual" ], "xbrltype": "domainItemType" }, "gblx_GbsGlobalBiopharmaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents GBS Global Biopharma, Inc.", "label": "GBS Global Biopharma, Inc [Member]" } } }, "localname": "GbsGlobalBiopharmaIncMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "gblx_IncomeTaxReconciliationAccruedInterestOnPriorYearTaxLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to accrued interest on previously reported income tax liabilities.", "label": "gblx_IncomeTaxReconciliationAccruedInterestOnPriorYearTaxLiabilities", "terseLabel": "Income Tax Reconciliation, Accrued Interest on Prior Year Tax Liabilities" } } }, "localname": "IncomeTaxReconciliationAccruedInterestOnPriorYearTaxLiabilities", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_IncomeTaxReconciliationPriorYearTaxPenalties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to prior year tax penalties.", "label": "gblx_IncomeTaxReconciliationPriorYearTaxPenalties", "terseLabel": "Income Tax Reconciliation, Prior Year Tax Penalties" } } }, "localname": "IncomeTaxReconciliationPriorYearTaxPenalties", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_IncreaseDecreaseInAccruedLiabilitiesExcludingInterestPayable": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid, excluding interest payable.", "label": "gblx_IncreaseDecreaseInAccruedLiabilitiesExcludingInterestPayable", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesExcludingInterestPayable", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "gblx_IncreaseDecreaseLiabilityDueFromExchangeReductionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of the increase (decrease) in addition to (to reduce) the original liability amount, as a result of an exchange reduction transaction.", "label": "gblx_IncreaseDecreaseLiabilityDueFromExchangeReductionPercentage", "terseLabel": "Increase (Decrease) Liability Due from Exchange Reduction, Percentage (Rate)" } } }, "localname": "IncreaseDecreaseLiabilityDueFromExchangeReductionPercentage", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "percentItemType" }, "gblx_IncreaseDecreaseLiabilityDueFromExchangeReductionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The monetary amount of the increase (decrease) in addition to (to reduce) the original liability amount, as a result of an exchange reduction transaction.", "label": "gblx_IncreaseDecreaseLiabilityDueFromExchangeReductionValue", "terseLabel": "Increase (Decrease) Liability Due from Exchange Reduction, Value" } } }, "localname": "IncreaseDecreaseLiabilityDueFromExchangeReductionValue", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_IndefinitelivedIntangibleAssetsPendingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NUmber of indefinite-lived intangible assets applications that are pending.", "label": "gblx_IndefinitelivedIntangibleAssetsPendingNumber", "terseLabel": "Indefinite-Lived Intangible Assets, Pending, Number" } } }, "localname": "IndefinitelivedIntangibleAssetsPendingNumber", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "gblx_InducedDividendFromExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The non-cash value of an induced dividend prompted by the exercise of warrants for securities which have a dividend.", "label": "Inducement dividend from warrant exercises" } } }, "localname": "InducedDividendFromExerciseOfWarrants", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "gblx_InducedDividendFromWarrantExercises": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the value of induced dividend from warrant exercises during the indicated time period.", "label": "gblx_InducedDividendFromWarrantExercises", "terseLabel": "Induced Dividend from Warrant Exercises" } } }, "localname": "InducedDividendFromWarrantExercises", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_InterestPayableAccruedPriorToExtinguishments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "With regard to the amount of interest payable on debt, including, but not limited to, trade payables, this element represents the portion accrued prior to extinguishments.", "label": "gblx_InterestPayableAccruedPriorToExtinguishments", "terseLabel": "Interest Payable, Accrued Prior to Extinguishments" } } }, "localname": "InterestPayableAccruedPriorToExtinguishments", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_IssuanceOfWarrantsToBrokers": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrants granted to brokers as payment for services rendered.", "label": "gblx_IssuanceOfWarrantsToBrokers", "terseLabel": "Compensation warrants" } } }, "localname": "IssuanceOfWarrantsToBrokers", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "gblx_JohnDavisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to John Davis.", "label": "John Davis [Member]" } } }, "localname": "JohnDavisMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_July2017ConvertibleNoteOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 6% convertible promissory note issued in the July 2017 Convertible Note Offering.", "label": "July 2017 Convertible Note Offering [Member]" } } }, "localname": "July2017ConvertibleNoteOfferingMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_KseniaGriswoldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Ksenia Griswold.", "label": "Ksenia Griswold [Member]" } } }, "localname": "KseniaGriswoldMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_LeslieBocskorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Leslie Bocskor.", "label": "Leslie Bocskor [Member]" } } }, "localname": "LeslieBocskorMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_LicensedPatentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to licensed patents.", "label": "Licensed Patents [Member]" } } }, "localname": "LicensedPatentsMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "gblx_LineOfCreditFacilityMaximumBorrowingCapacityIncreased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount increased in maximum borrowing capacity for a line of credit facility.", "label": "gblx_LineOfCreditFacilityMaximumBorrowingCapacityIncreased", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity, Increased" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncreased", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_LitigationSettlementAmountFinalSettlement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The final amount settlement from litigation.", "label": "gblx_LitigationSettlementAmountFinalSettlement", "terseLabel": "Litigation Settlement, Amount Final Settlement" } } }, "localname": "LitigationSettlementAmountFinalSettlement", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_LitigationSettlementOneTimeRequiredPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The one time required payment for litigation settlement.", "label": "gblx_LitigationSettlementOneTimeRequiredPayment", "terseLabel": "Litigation Settlement, One Time Required Payment" } } }, "localname": "LitigationSettlementOneTimeRequiredPayment", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_LitigationSettlementPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of payment for litigation settlement.", "label": "gblx_LitigationSettlementPayment", "terseLabel": "Litigation Settlement, Payment" } } }, "localname": "LitigationSettlementPayment", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_LitigationSettlementWeeklyRequiredPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The payment amount required per week until the judgment settlement is paid.", "label": "gblx_LitigationSettlementWeeklyRequiredPayment", "terseLabel": "Litigation Settlement, Weekly Required Payment" } } }, "localname": "LitigationSettlementWeeklyRequiredPayment", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_March2017ConvertibleNoteOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the March 2017 Convertible Note Offering.", "label": "March 2017 Convertible Note Offering [Member]" } } }, "localname": "March2017ConvertibleNoteOfferingMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_MarchAndJuly2017ConvertibleNoteOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the March and July 2017 offering.", "label": "March And July 2017 Convertible Note Offering [Member]" } } }, "localname": "MarchAndJuly2017ConvertibleNoteOfferingMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_MembershipInterestPurchaseAgreementForSaleOfInterestInGBSciencesNopahLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding the membership interest purchase agreement for the sale of interest in GB Sciences Nopah, LLC.", "label": "Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member]" } } }, "localname": "MembershipInterestPurchaseAgreementForSaleOfInterestInGBSciencesNopahLLCMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "gblx_NevadaMedicalMarijuanaProductionLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Nevada Medical Marijuana Production License Agreement.", "label": "Nevada Medical Marijuana Production License Agreement [Member]" } } }, "localname": "NevadaMedicalMarijuanaProductionLicenseAgreementMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "gblx_NevadaSubsidiariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Nevada subsidiaries.", "label": "Nevada Subsidiaries [Member]" } } }, "localname": "NevadaSubsidiariesMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details-parentheticals" ], "xbrltype": "domainItemType" }, "gblx_NotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to re-pay a note.", "label": "Note Payable [Member]" } } }, "localname": "NotePayableMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "gblx_NoteReceivableInterestOnlyMonthly": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The monthly interest only amount for the note receivable to the Company.", "label": "gblx_NoteReceivableInterestOnlyMonthly", "terseLabel": "Note Receivable, Interest Only, Monthly" } } }, "localname": "NoteReceivableInterestOnlyMonthly", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_NoteReceivableQuarterlyPrincipalAndInterestInstallment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of the aggregate principal and interest due in quarterly installments.", "label": "gblx_NoteReceivableQuarterlyPrincipalAndInterestInstallment", "terseLabel": "Note Receivable, Quarterly Principal and Interest Installment" } } }, "localname": "NoteReceivableQuarterlyPrincipalAndInterestInstallment", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_NotesAndAccruedInterestPayableExchangeReductionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of the balance of retired (or transferred) notes and accrued interest retired at the time of the transaction.", "label": "gblx_NotesAndAccruedInterestPayableExchangeReductionPercentage", "terseLabel": "Notes and Accrued Interest Payable, Exchange Reduction, Percentage (Rate)" } } }, "localname": "NotesAndAccruedInterestPayableExchangeReductionPercentage", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "percentItemType" }, "gblx_NotesPayableCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of current and long-term notes payable due.", "label": "gblx_NotesPayableCurrentAndNoncurrent", "terseLabel": "Notes Payable, Current and Noncurrent" } } }, "localname": "NotesPayableCurrentAndNoncurrent", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_NotesPayablePrincipalAndInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value of notes payable, principal and interest, at the reporting date.", "label": "gblx_NotesPayablePrincipalAndInterest", "terseLabel": "Notes Payable, Principal and Interest" } } }, "localname": "NotesPayablePrincipalAndInterest", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_NotesPayablePrincipalAndInterestAfterModifiedTerms": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of notes payable, principal and interest, at the reporting date after agreement terms modification.", "label": "gblx_NotesPayablePrincipalAndInterestAfterModifiedTerms", "terseLabel": "Notes Payable, Principal and Interest, After Modified Terms" } } }, "localname": "NotesPayablePrincipalAndInterestAfterModifiedTerms", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_NotesReceivableAdditionalAdvances": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of additional advances from a notes receivable.", "label": "gblx_NotesReceivableAdditionalAdvances", "terseLabel": "Notes Receivable, Additional Advances" } } }, "localname": "NotesReceivableAdditionalAdvances", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_NotesReceivableInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The interest rate of the notes receivable.", "label": "gblx_NotesReceivableInterestRate", "terseLabel": "Notes Receivable, Interest Rate" } } }, "localname": "NotesReceivableInterestRate", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "percentItemType" }, "gblx_NotesReceivableIssued": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details": { "order": 3.0, "parentTag": "gblx_DeconsolidationEntitysInterestNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of notes receivable issued.", "label": "Note receivable from sale of Nevada Subsidiaries", "verboseLabel": "8% Note Receivable due December 31, 2024" } } }, "localname": "NotesReceivableIssued", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details" ], "xbrltype": "monetaryItemType" }, "gblx_NotesReceivableMaximumAllowedPrepaymentsOnNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The maximum allowed prepayments on note for a notes receivable.", "label": "gblx_NotesReceivableMaximumAllowedPrepaymentsOnNote", "terseLabel": "Notes Receivable, Maximum Allowed Prepayments On Note" } } }, "localname": "NotesReceivableMaximumAllowedPrepaymentsOnNote", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_NumberOfCommonStockReceivedPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock received per unit.", "label": "gblx_NumberOfCommonStockReceivedPerUnit", "terseLabel": "Number of Common Stock Received, Per Unit (in shares)" } } }, "localname": "NumberOfCommonStockReceivedPerUnit", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "gblx_NumberOfWarrantReceivedPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrant received per unit.", "label": "gblx_NumberOfWarrantReceivedPerUnit", "terseLabel": "Number of Warrant Received, Per Unit (in shares)" } } }, "localname": "NumberOfWarrantReceivedPerUnit", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "gblx_OfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents officers and directors.", "label": "Officers and Directors [Member]" } } }, "localname": "OfficersAndDirectorsMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_OperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforwards that are not subject to expiration dates.", "label": "gblx_OperatingLossCarryforwardsNotSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Not Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforwards that are subject to expiration dates.", "label": "gblx_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_OwnershipOfLicense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the ownership interest of a license to produce a good or service.", "label": "gblx_OwnershipOfLicense", "terseLabel": "Ownership of License" } } }, "localname": "OwnershipOfLicense", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "percentItemType" }, "gblx_PatentFilingAndDraftingCostsCapitalizedInIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents amount of patent filing and drafting costs capitalized in intangible assets.", "label": "Patent acquisition costs capitalized in intangible assets" } } }, "localname": "PatentFilingAndDraftingCostsCapitalizedInIntangibleAssets", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "gblx_PaymentOfServicesProvidedByContractorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents payments of services provided by contractor.", "label": "Payment of Services Provided by Contractor [Member]" } } }, "localname": "PaymentOfServicesProvidedByContractorMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "gblx_PaymentsToAcquireLicense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from amounts paid for licensing rights.", "label": "gblx_PaymentsToAcquireLicense", "terseLabel": "Payments to Acquire License" } } }, "localname": "PaymentsToAcquireLicense", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_ProceedsFromDivestitureOfBusinessAdvancesReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the advance payments received from the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries.", "label": "Advancements", "terseLabel": "Proceeds From Divestiture of Business, Advances Received" } } }, "localname": "ProceedsFromDivestitureOfBusinessAdvancesReceived", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details-parentheticals" ], "xbrltype": "monetaryItemType" }, "gblx_ProductionLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the production license found within the Nevada Medical Marijuana Production License Agreement.", "label": "Production License [Member]" } } }, "localname": "ProductionLicenseMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "gblx_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A signed note containing a written promise to pay a stated amount to the holder at a specified date or on demand.", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_QuarterlyInterestOnlyPaymentsOnNoteReceivableYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The duration (in years) required for quarterly interest only payments on a note receivable.", "label": "gblx_QuarterlyInterestOnlyPaymentsOnNoteReceivableYears", "terseLabel": "Quarterly Interest Only Payments on Note Receivable, Years" } } }, "localname": "QuarterlyInterestOnlyPaymentsOnNoteReceivableYears", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "pureItemType" }, "gblx_ReductionInCostBasisOfFixedAssetRelatedToLitigation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the reduction in the cost basis of the fixed asset related to litigation.", "label": "gblx_ReductionInCostBasisOfFixedAssetRelatedToLitigation", "terseLabel": "Reduction in Cost Basis of Fixed Asset Related to Litigation" } } }, "localname": "ReductionInCostBasisOfFixedAssetRelatedToLitigation", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_RepaymentOfIliadNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the repayment of the Iliad note.", "label": "Repayment of Iliad Note [Member]" } } }, "localname": "RepaymentOfIliadNoteMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_RepaymentOfNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of repayment on outstanding notes payable.", "label": "gblx_RepaymentOfNotesPayable", "terseLabel": "Repayment of Notes Payable" } } }, "localname": "RepaymentOfNotesPayable", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_RepaymentsOfPrincipalNotesPayableAndOperatingLeaseObligation": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the cash outflow during the period for principal payments on notes payable and operating lease obligation.", "label": "gblx_RepaymentsOfPrincipalNotesPayableAndOperatingLeaseObligation", "negatedLabel": "Principal payment on notes payable" } } }, "localname": "RepaymentsOfPrincipalNotesPayableAndOperatingLeaseObligation", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "gblx_ReplacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the replacement warrants.", "label": "Replacement Warrants [Member]" } } }, "localname": "ReplacementWarrantsMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_SaleOfInterestPercentageOfOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of ownership for sale of interest.", "label": "gblx_SaleOfInterestPercentageOfOwnership", "terseLabel": "Sale of Interest, Percentage of Ownership" } } }, "localname": "SaleOfInterestPercentageOfOwnership", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual" ], "xbrltype": "percentItemType" }, "gblx_SaleOfStockPercentageOfOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock sold in the stock transaction.", "label": "gblx_SaleOfStockPercentageOfOwnership", "terseLabel": "Sale of Stock, Percentage of Ownership" } } }, "localname": "SaleOfStockPercentageOfOwnership", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "percentItemType" }, "gblx_SaleOfUnitPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per unit amount received for each unit sold.", "label": "gblx_SaleOfUnitPricePerUnit", "terseLabel": "Sale of Unit, Price Per Unit (in dollars per share)" } } }, "localname": "SaleOfUnitPricePerUnit", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "perShareItemType" }, "gblx_SaleOfUnitsMaximumUnitsAllowedInPrivatePlacement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum units allowed in private placement.", "label": "gblx_SaleOfUnitsMaximumUnitsAllowedInPrivatePlacement", "terseLabel": "Sale of Units, Maximum Units Allowed in Private Placement" } } }, "localname": "SaleOfUnitsMaximumUnitsAllowedInPrivatePlacement", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_ScheduleOfDeconsolidationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of deconsolidation.", "label": "Schedule of Deconsolidation [Table Text Block]" } } }, "localname": "ScheduleOfDeconsolidationTableTextBlock", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-tables" ], "xbrltype": "textBlockItemType" }, "gblx_ScientistAndResearcherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents scientist and researcher.", "label": "Scientist and Researcher [Member]" } } }, "localname": "ScientistAndResearcherMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_SegmentContinuingAndDiscontinuedOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents both the component of an entity expected to operate in the foreseeable future, and the component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Segment, Continuing and Discontinued Operations [Member]" } } }, "localname": "SegmentContinuingAndDiscontinuedOperationsMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "domainItemType" }, "gblx_SeniorSecuredConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A convertible promissory note which takes priority over other debt securities. In the event the issuer goes bankrupt, senior secured convertible promissorry note holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors.", "label": "Senior Secured Convertible Promissory Note [Member]" } } }, "localname": "SeniorSecuredConvertiblePromissoryNoteMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "gblx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAfterModificationFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options granted after modification. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "gblx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAfterModificationFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAfterModificationFairValue", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodBeforeModificationFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options granted before modification. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "gblx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodBeforeModificationFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodBeforeModificationFairValue", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_ShortTermBorrowingsContinuingOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer, for debt instruments classified as continuing operations.", "label": "gblx_ShortTermBorrowingsContinuingOperations", "terseLabel": "Total short term notes and convertible notes payable classified as continuing operations" } } }, "localname": "ShortTermBorrowingsContinuingOperations", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "gblx_ShortTermBorrowingsDiscontinuedOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer, for debt instruments classified as discontinued operations.", "label": "gblx_ShortTermBorrowingsDiscontinuedOperations", "negatedLabel": "Less: Notes payable classified as discontinued operations, carrying value" } } }, "localname": "ShortTermBorrowingsDiscontinuedOperations", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "gblx_StockOptionsIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of stock options issued for services in noncash or partial noncash transaction.", "label": "Stock options issued for preparing capitalized patent applications", "terseLabel": "Stock options issued as compensation for drafting and filing patents" } } }, "localname": "StockOptionsIssuedForServices", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "monetaryItemType" }, "gblx_TecoSaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the company's disposal of Teco segment by sale transaction.", "label": "Teco Sale [Member]" } } }, "localname": "TecoSaleMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_TecoSubsidiariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Teco subsidiaries.", "label": "Teco Subsidiaries [Member]" } } }, "localname": "TecoSubsidiariesMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "gblx_The0PercentNotePayableDatedOctober232017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 0% note payable dated October 23, 2017.", "label": "The 0% Note Payable Dated October 23, 2017 [Member]" } } }, "localname": "The0PercentNotePayableDatedOctober232017Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "gblx_The2014EquityCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2014 Equity Compensation Plan.", "label": "The 2014 Equity Compensation Plan [Member]" } } }, "localname": "The2014EquityCompensationPlanMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual" ], "xbrltype": "domainItemType" }, "gblx_The2021EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2021 Equity Incentive Plan.", "label": "The 2021 Equity Incentive Plan [Member]" } } }, "localname": "The2021EquityIncentivePlanMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual" ], "xbrltype": "domainItemType" }, "gblx_The6ConvertibleNotePayableMatureInDecember2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to the 6% convertible notes payable that mature in December 2021", "label": "The 6 % Convertible Note Payable Mature in December 2021 [Member]" } } }, "localname": "The6ConvertibleNotePayableMatureInDecember2021Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_The6ConvertibleNotePayableMatureInDecember2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to the 6% convertible notes payable that mature in December 2023.", "label": "The 6 % Convertible Note Payable Mature in December 2023 [Member]" } } }, "localname": "The6ConvertibleNotePayableMatureInDecember2023Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_The6NotesPayableDueJuly12022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding the 6% notes payable due July 1, 2022.", "label": "The 6% Notes Payable Due July 1, 2022 [Member]" } } }, "localname": "The6NotesPayableDueJuly12022Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "gblx_The6PercentConvertibleNotePayableDatedDecember312023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 6 % convertible note payable dated December 31, 2023.", "label": "The 6 % Convertible Note Payable Dated December 31, 2023 [Member]" } } }, "localname": "The6PercentConvertibleNotePayableDatedDecember312023Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_The6PercentConvertibleNotePayableIssuedWithInMoneyConversionFeaturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 6% convertible note payable issued in money conversion features.", "label": "The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member]" } } }, "localname": "The6PercentConvertibleNotePayableIssuedWithInMoneyConversionFeaturesMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_The6PercentNotePayableDatedDecember312023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 6 Percent convertible notes payable dated December 31, 2023.", "label": "The 6 % Note Payable Dated December 31, 2023 [Member]" } } }, "localname": "The6PercentNotePayableDatedDecember312023Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "gblx_The6PercentNotePayableDatedSeptember302023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 6 Percent convertible note payable dated September 30, 2023.", "label": "The 6 % Note Payable Dated September 30, 2023 [Member]" } } }, "localname": "The6PercentNotePayableDatedSeptember302023Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "gblx_The6PercentNotePayableDueNovember302018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the 6% Note Payable due November 30, 2018.", "label": "The 6% Note Payable Due November 30, 2018 [Member]" } } }, "localname": "The6PercentNotePayableDueNovember302018Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "gblx_The6PercentNotesPayableDueJanuary182022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding the 6% notes payable due January 18, 2022.", "label": "The 6% Notes Payable Due January 18, 2022 [Member]" } } }, "localname": "The6PercentNotesPayableDueJanuary182022Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "gblx_The8PercentConvertiblePromissoryNoteDatedApril232019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 8% Convertible Promissory Note dated April 23, 2019 issued upon entering of the Note Purchase Agreement with Iliad Research and Trading, L.P.", "label": "The 8% Convertible Promissory Note Dated April 23, 2019 [Member]" } } }, "localname": "The8PercentConvertiblePromissoryNoteDatedApril232019Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_The8PercentLineOfCreditDatedJuly242020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding the 8% line of credit dated July 24, 2020.", "label": "The 8% Line of Credit Dated July 24, 2020 [Member]" } } }, "localname": "The8PercentLineOfCreditDatedJuly242020Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "gblx_The8PercentLineOfCreditDatedNovember272019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information regarding the 8% line of credit dated November 27, 2019.", "label": "The 8% Line of Credit Dated November 27, 2019 [Member]" } } }, "localname": "The8PercentLineOfCreditDatedNovember272019Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "gblx_The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 8% Senior Secured Convertible Promissory Note dated February 28, 2019 issued in relation to the Note Purchase Agreement and Security Agreement with CSW Ventures, LP (together, \"CSW Note\").", "label": "The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]" } } }, "localname": "The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_TheAmended8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the amended 8% Senior Secured Convertible Promissory Note dated February 28, 2019 issued upon entering into the Amendment to Note Documents and the Amended and Restated 8% Senior Secured Promissory Note (together, \"CSW Amendment\").", "label": "The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]" } } }, "localname": "TheAmended8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "gblx_TheJuly24NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the July 24 note.", "label": "The July 24 Note [Member]" } } }, "localname": "TheJuly24NoteMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "gblx_ThreeInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to three investors.", "label": "Three Investors [Member]" } } }, "localname": "ThreeInvestorsMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_UnpaidSeveranceCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to unpaid severance compensation.", "label": "Unpaid Severance Compensation [Member]" } } }, "localname": "UnpaidSeveranceCompensationMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_WarrantsIssuedInMarch2017AndJuly2017ConvertibleNoteOfferingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants issued in March 2017 and July 2017 convertible note offerings.", "label": "Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member]" } } }, "localname": "WarrantsIssuedInMarch2017AndJuly2017ConvertibleNoteOfferingsMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_WarrantsIssuedInMarch2017ConvertibleNoteOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the warrants issued in the March 2017 Convertible Note Offering.", "label": "Warrants Issued in March 2017 Convertible Note Offering [Member]" } } }, "localname": "WarrantsIssuedInMarch2017ConvertibleNoteOfferingMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_WarrantsIssuedInSeptember302023ConvertibleNoteOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to warrants issued in September 30, 2023 as part of the convertible notes offering.", "label": "Warrants Issued in September 30, 2023, Convertible Note Offering [Member]" } } }, "localname": "WarrantsIssuedInSeptember302023ConvertibleNoteOfferingMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_WarrantsIssuedToInvestorsInPrivatePlacementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents all warrants issued to investors in private placements.", "label": "Warrants Issued to Investors in Private Placements [Member]" } } }, "localname": "WarrantsIssuedToInvestorsInPrivatePlacementsMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_WarrantsIssuedToResearcherAsCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants issued to researcher as compensation.", "label": "Warrants Issued to Researcher as Compensation [Member]" } } }, "localname": "WarrantsIssuedToResearcherAsCompensationMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "gblx_WarrantsRelatedToJuly2017ConvertibleNoteOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the warrants which are related to the July 2017 Convertible Note Offering.", "label": "Warrants Related to July 2017 Convertible Note Offering [Member]" } } }, "localname": "WarrantsRelatedToJuly2017ConvertibleNoteOfferingMember", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "gblx_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the value of current assets are greater than (less than) current liabilities for the entity.", "label": "gblx_WorkingCapitalDeficit", "terseLabel": "Working Capital (Deficit)" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://gbsciences.com/20220331", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual" ], "xbrltype": "monetaryItemType" }, "gblx_statement-statement-note-10-employee-benefit-plan-assumptions-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Employee Benefit Plan - Assumptions (Details)" } } }, "localname": "statement-statement-note-10-employee-benefit-plan-assumptions-details", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-10-employee-benefit-plan-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Employee Benefit Plan - Option Activity (Details)" } } }, "localname": "statement-statement-note-10-employee-benefit-plan-option-activity-details", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-10-employee-benefit-plan-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Employee Benefit Plan" } } }, "localname": "statement-statement-note-10-employee-benefit-plan-tables", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Sale of Membership Interests in Nevada Subsidiaries - Gain on Deconsolidation (Details)" } } }, "localname": "statement-statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details-parentheticals": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Sale of Membership Interests in Nevada Subsidiaries - Gain on Deconsolidation (Details) (Parentheticals)" } } }, "localname": "statement-statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details-parentheticals", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Sale of Membership Interests in Nevada Subsidiaries" } } }, "localname": "statement-statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-tables", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-4-discontinued-operations-discontinued-operations-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Discontinued Operations - Discontinued Operations (Details)" } } }, "localname": "statement-statement-note-4-discontinued-operations-discontinued-operations-details", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Discontinued Operations - Lease Costs Recorded in the Company's Financial Statements (Details)" } } }, "localname": "statement-statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-4-discontinued-operations-schedule-of-inventory-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Discontinued Operations - Schedule of Inventory (Details)" } } }, "localname": "statement-statement-note-4-discontinued-operations-schedule-of-inventory-details", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-4-discontinued-operations-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Discontinued Operations" } } }, "localname": "statement-statement-note-4-discontinued-operations-tables", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Notes Payable and Line of Credit - Summary of Notes and Convertible Notes Payable (Details)" } } }, "localname": "statement-statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-5-notes-payable-and-line-of-credit-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Notes Payable and Line of Credit" } } }, "localname": "statement-statement-note-5-notes-payable-and-line-of-credit-tables", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Income Taxes - Reconciliation of Effective Income Tax Expense (Benefit) (Details)" } } }, "localname": "statement-statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-8-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Income Taxes" } } }, "localname": "statement-statement-note-8-income-taxes-tables", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-9-capital-transactions-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Capital Transactions" } } }, "localname": "statement-statement-note-9-capital-transactions-tables", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-note-9-capital-transactions-warrant-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Capital Transactions - Warrant Activity (Details)" } } }, "localname": "statement-statement-note-9-capital-transactions-warrant-activity-details", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "gblx_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://gbsciences.com/20220331", "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r81", "r83", "r140", "r141", "r261", "r298" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r233", "r235", "r236", "r237", "r260", "r297", "r332", "r334", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r545", "r546", "r559", "r560" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r233", "r235", "r236", "r237", "r260", "r297", "r332", "r334", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r545", "r546", "r559", "r560" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details-parentheticals", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details-parentheticals", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r227", "r233", "r235", "r236", "r237", "r260", "r297", "r329", "r332", "r334", "r365", "r366", "r367", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r545", "r546", "r559", "r560" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r227", "r233", "r235", "r236", "r237", "r260", "r297", "r329", "r332", "r334", "r365", "r366", "r367", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r545", "r546", "r559", "r560" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r82", "r83", "r140", "r141", "r261", "r298" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r197", "r470" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r67", "r476" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r524", "r554" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "us-gaap_AccountsReceivableNet", "terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Total" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r198", "r199" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "us-gaap_AccountsReceivableNetCurrent", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r48", "r506", "r527" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Income tax payable", "verboseLabel": "Income tax payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r72" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities", "verboseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r52", "r476" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r144", "r145", "r146", "r372", "r373", "r374", "r434" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r310", "r315", "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "terseLabel": "Beneficial conversion feature on notes payable" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r337", "r376", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Share based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r255", "r310", "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Compensation warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r369" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r102", "r120", "r280", "r451" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount and beneficial conversion feature", "terseLabel": "Amortization of Debt Discount (Premium)" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r120", "r206", "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "us-gaap_AmortizationOfIntangibleAssets", "terseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r120", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "us-gaap_AssetImpairmentCharges", "terseLabel": "Asset Impairment Charges, Total" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r44", "r135", "r183", "r186", "r192", "r201", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r252", "r253", "r421", "r427", "r440", "r474", "r476", "r504", "r526" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r38", "r65", "r135", "r201", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r252", "r253", "r421", "r427", "r440", "r474", "r476" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r3", "r4", "r25", "r27", "r31", "r219", "r222" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Current assets from discontinued operations" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r35", "r143", "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r36", "r41", "r122" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r114", "r122", "r128" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "CASH AND CASH EQUIVALENTS AT END OF YEAR FROM CONTINUING OPERATIONS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r114", "r122", "r128" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF YEAR", "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r114", "r441" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "auth_ref": [ "r114" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net cash used in financing activities of discontinued operations" } } }, "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r24", "r114" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net cash provided by/(used in) investing activities of discontinued operations" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r24", "r114" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash used in operating activities of discontinued operations", "terseLabel": "Cash Provided by (Used in) Operating Activities, Discontinued Operations" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "us-gaap_CashUninsuredAmount", "terseLabel": "Cash, Uninsured Amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-14-concentrations-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r316", "r339" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "periodEndLabel": "Outstanding (in shares)", "periodStartLabel": "Outstanding (in shares)", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_CollateralAxis": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Information by category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Axis]" } } }, "localname": "CollateralAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Domain]" } } }, "localname": "CollateralDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CollateralPledgedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pledge of specific property to serve as protection against default.", "label": "Collateral Pledged [Member]" } } }, "localname": "CollateralPledgedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r77", "r513", "r534" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r228", "r229", "r230", "r238", "r555" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r144", "r145", "r434" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r51", "r310" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r51", "r476" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, $0.0001 par value, 600,000,000 shares authorized, 325,037,557 and 315,340,411 outstanding at March 31, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r327", "r328", "r335", "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-14-concentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r130", "r423" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r254", "r257", "r258", "r260", "r270", "r271", "r272", "r276", "r277", "r278", "r279", "r280", "r288", "r289", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r76" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable, net of unamortized discount of $99,489 and $154,590 at March 31, 2022 and 2021, respectively", "terseLabel": "Convertible Notes Payable, Noncurrent", "verboseLabel": "Convertible notes payable, net" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r49", "r507", "r529", "r553" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "us-gaap_ConvertibleNotesPayable", "terseLabel": "Convertible Notes Payable, Total" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r72" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Notes and convertible notes payable, net of unamortized discount of $1,765 and $296,504 at March 31, 2022 and 2021, respectively", "terseLabel": "Convertible Notes Payable, Current" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r47", "r505", "r522", "r553" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r99", "r135", "r201", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250", "r252", "r253", "r440" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "us-gaap_CostOfRevenue", "negatedLabel": "Cost of goods sold" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r136", "r398", "r405", "r406" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total provision for income taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r125", "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock issued upon conversion of notes payable" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r125", "r127" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r125", "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_DebtConversionOriginalDebtAmount1", "terseLabel": "Debt Conversion, Original Debt, Amount" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "us-gaap_DebtDefaultLongtermDebtAmount", "terseLabel": "Debt Instrument, Debt Default, Amount" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r132", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r274", "r281", "r282", "r283", "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r47", "r48", "r49", "r134", "r142", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r270", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r288", "r289", "r290", "r291", "r454", "r505", "r507", "r522" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature", "terseLabel": "Debt Instrument, Convertible, Beneficial Conversion Feature", "verboseLabel": "Beneficial conversion feature on notes payable" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r259", "r286" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1", "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "auth_ref": [ "r75", "r259", "r311", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.", "label": "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments", "terseLabel": "Debt Instrument, Convertible, Number of Equity Instruments" } } }, "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r257", "r288", "r289", "r452", "r454", "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Short-Term Notes Payable", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r74", "r258" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r76", "r134", "r142", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r270", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r288", "r289", "r290", "r291", "r454" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Year)" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r270", "r451", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "us-gaap_DebtInstrumentUnamortizedDiscount", "terseLabel": "Debt Instrument, Unamortized Discount, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r451", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Unamortized discount, current", "negatedLabel": "Discount, short-term notes payable", "terseLabel": "Debt Instrument, Unamortized Discount, Current" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r451", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Unamortized discount, noncurrent", "negatedLabel": "Discount, short-term notes payable", "terseLabel": "Debt Instrument, Unamortized Discount, Noncurrent" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r270", "r284", "r288", "r289", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeconsolidationGainOrLossAmount": { "auth_ref": [ "r426" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 8.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.", "label": "Gain on deconsolidation", "negatedLabel": "Gain on deconsolidation", "terseLabel": "Deconsolidation, Gain (Loss), Amount", "verboseLabel": "GAIN ON DECONSOLIDATION" } } }, "localname": "DeconsolidationGainOrLossAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r390" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r392" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r396", "r397" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment", "verboseLabel": "Impairment of long-lived assets" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r396", "r397" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": { "auth_ref": [ "r396", "r397" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.", "label": "Other temporary items", "negatedLabel": "Other temporary items" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r391" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r396", "r397" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Depreciation and Amortization expense" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "us-gaap_DepositsAssetsNoncurrent", "terseLabel": "Deposits Assets, Noncurrent", "verboseLabel": "Deposits and other noncurrent assets" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r120", "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "us-gaap_Depreciation", "terseLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r120", "r220" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-14-concentrations", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-2-going-concern", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions" ], "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r11", "r12", "r13", "r14", "r15", "r22", "r94", "r538" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "totalLabel": "NET LOSS BEFORE INCOME TAXES" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.", "label": "Discontinued Operations, Disposed of by Sale [Member]" } } }, "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember": { "auth_ref": [ "r6", "r7", "r10" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components classified as held-for-sale or disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]" } } }, "localname": "DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables" ], "xbrltype": "domainItemType" }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "auth_ref": [ "r16", "r32" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.", "label": "Discontinued Operations, Policy [Policy Text Block]" } } }, "localname": "DiscontinuedOperationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "auth_ref": [ "r3", "r4", "r25", "r27", "r31", "r217", "r222" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Long term assets from discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r3", "r4", "r25", "r222" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "negatedLabel": "Less: cash and cash equivalents classified as discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration", "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r23" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 1.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r33", "r226" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r331", "r333" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DueToOfficersOrStockholdersCurrent": { "auth_ref": [ "r45", "r468", "r523", "r552" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Indebtedness to related parties", "verboseLabel": "Indebtedness to related parties" } } }, "localname": "DueToOfficersOrStockholdersCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r139", "r244", "r246", "r247", "r251", "r252", "r253", "r468", "r511", "r536" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent", "terseLabel": "Due to Related Parties, Total" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r96", "r149", "r150", "r151", "r152", "r153", "r157", "r159", "r163", "r164", "r165", "r168", "r169", "r435", "r436", "r518", "r541" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per common share \u2013 basic and diluted" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r87", "r88", "r89", "r144", "r145", "r146", "r148", "r154", "r156", "r170", "r202", "r310", "r315", "r372", "r373", "r374", "r401", "r402", "r434", "r442", "r443", "r444", "r445", "r446", "r447", "r464", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "us-gaap_ExtinguishmentOfDebtAmount", "terseLabel": "Extinguishment of Debt, Amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment of Debt, Type [Domain]" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r457", "r460", "r463" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance leases - interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "us-gaap_FinanceLeaseLiabilityCurrent", "verboseLabel": "Finance lease obligations, current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r456" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "us-gaap_FinanceLeaseLiabilityNoncurrent", "verboseLabel": "Finance lease obligations, long term" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r457", "r460", "r463" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance leases - amortization of ROU assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r42", "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r207", "r209", "r212", "r215", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r207", "r211" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r212", "r489" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, net of accumulated amortization of $104,201 and $43,096 at March 31, 2022 and 2021, respectively", "terseLabel": "Finite-Lived Intangible Assets, Net, Ending Balance" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r120" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Loss on disposal", "negatedLabel": "Loss on disposal of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r120", "r292", "r293" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on extinguishment", "negatedLabel": "Gain on extinguishment", "terseLabel": "Gain (Loss) on Extinguishment of Debt, Total" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r100" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses", "verboseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r336", "r338", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [ "r336", "r338", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r97", "r135", "r183", "r185", "r188", "r191", "r193", "r201", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250", "r252", "r253", "r440" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 0.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit (loss)" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r216", "r225" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r98", "r121", "r149", "r150", "r151", "r152", "r161", "r165", "r419" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "us-gaap_IncomeLossFromContinuingOperations", "totalLabel": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r93", "r183", "r185", "r188", "r191", "r193", "r503", "r515", "r520", "r542" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "LOSS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r135", "r147", "r183", "r185", "r188", "r191", "r193", "r201", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250", "r252", "r253", "r420", "r436", "r440" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "totalLabel": "LOSS FROM CONTINUING OPERATIONS" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r90", "r96", "r147", "r149", "r150", "r151", "r152", "r159", "r163", "r164", "r436", "r514", "r516", "r518", "r537" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare", "terseLabel": "Continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r11", "r12", "r13", "r14", "r15", "r28", "r31", "r410", "r538" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Net loss from discontinued operations (Note 4)", "terseLabel": "Loss from discontinued operations", "totalLabel": "NET LOSS" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r94", "r96", "r160", "r163", "r164", "r518", "r538", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "terseLabel": "Discontinued operations (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r331", "r333" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r137", "r386", "r388", "r394", "r403", "r407", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r138", "r155", "r156", "r182", "r384", "r404", "r408", "r543" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax expense (Note 8)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems": { "auth_ref": [ "r409" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current tax expense (benefit) and deferred tax expense (benefit) pertaining to income (loss) from continuing operations and income (loss) from discontinued operations.", "label": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations", "totalLabel": "Total income tax expense" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r86", "r382", "r383", "r388", "r389", "r393", "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r385" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details": { "order": 5.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r385" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Tax expense/(benefit) computed at U.S. statutory rates" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r385" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details": { "order": 4.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Other permanent items" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).", "label": "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes", "terseLabel": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount" } } }, "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r116", "r124" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "us-gaap_IncomeTaxesPaid", "verboseLabel": "Cash paid for income tax" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r119" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r119" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "us-gaap_IncreaseDecreaseInDueToRelatedParties", "verboseLabel": "Indebtedness to related parties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r119" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "us-gaap_IncreaseDecreaseInInterestPayableNet", "verboseLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesReceivableCurrent": { "auth_ref": [ "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans.", "label": "us-gaap_IncreaseDecreaseInNotesReceivableCurrent", "terseLabel": "Increase (Decrease) in Notes Receivable, Current" } } }, "localname": "IncreaseDecreaseInNotesReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r119" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r208", "r214" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r214" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill", "terseLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r208", "r214" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_InducedConversionOfConvertibleDebtExpense": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.", "label": "us-gaap_InducedConversionOfConvertibleDebtExpense", "terseLabel": "Induced Conversion of Convertible Debt Expense" } } }, "localname": "InducedConversionOfConvertibleDebtExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDebtExpense": { "auth_ref": [ "r450" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.", "label": "us-gaap_InterestAndDebtExpense", "terseLabel": "Interest and Debt Expense, Total" } } }, "localname": "InterestAndDebtExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r91", "r181", "r449", "r453", "r519" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r102", "r278", "r287", "r290", "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt, Total" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r112", "r115", "r124" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "us-gaap_InterestPaidNet", "verboseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r72" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r512", "r535" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "us-gaap_InterestPayableCurrentAndNoncurrent", "terseLabel": "Interest Payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r57" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r63" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "us-gaap_InventoryGross", "totalLabel": "Subtotal" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r37", "r63", "r476" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "us-gaap_InventoryNet", "terseLabel": "Inventory, Net, Total", "totalLabel": "Total inventory (discontinued operations)", "verboseLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r59" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details": { "order": 0.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r63", "r205" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "negatedLabel": "Allowance to reduce inventory to NRV" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r58" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in progress" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_JudicialRulingMember": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.", "label": "Judicial Ruling [Member]" } } }, "localname": "JudicialRulingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r462", "r463" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost, discontinued operations" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeFinanceLeaseDiscountRate": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of finance lease payments.", "label": "us-gaap_LesseeFinanceLeaseDiscountRate", "terseLabel": "Lessee, Finance Lease, Discount Rate" } } }, "localname": "LesseeFinanceLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r71", "r135", "r187", "r201", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250", "r252", "r253", "r422", "r427", "r428", "r440", "r474", "r475" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r56", "r135", "r201", "r440", "r476", "r508", "r532" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r73", "r135", "r201", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250", "r252", "r253", "r422", "r427", "r428", "r440", "r474", "r475", "r476" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r3", "r4", "r25", "r27", "r31", "r219", "r222" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Current liabilities from discontinued operations" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "auth_ref": [ "r3", "r4", "r25", "r27", "r31", "r217", "r222" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Long term liabilities from discontinued operations" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r49", "r507", "r522" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "us-gaap_LineOfCredit", "terseLabel": "Long-term Line of Credit, Total" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "us-gaap_LitigationSettlementAmountAwardedToOtherParty", "terseLabel": "Litigation Settlement, Amount Awarded to Other Party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r49", "r271", "r285", "r288", "r289", "r507", "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Carrying value, long-term notes payable" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r76", "r240" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r231", "r232", "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "us-gaap_LossContingencyDamagesSoughtValue", "terseLabel": "Loss Contingency, Damages Sought, Value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "us-gaap_MinorityInterestOwnershipPercentageByParent", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r114" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r114" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "totalLabel": "Net cash used in financing activities of continuing operations" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r114" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r114" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "totalLabel": "Net cash provided by investing activities of continuing operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r114", "r118", "r121" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "terseLabel": "Net Cash Provided by (Used in) Operating Activities, Total", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r114", "r118", "r121" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "totalLabel": "Net cash used in operating activities of continuing operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r31", "r84", "r85", "r89", "r95", "r121", "r135", "r147", "r149", "r150", "r151", "r152", "r155", "r156", "r161", "r183", "r185", "r188", "r191", "r193", "r201", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250", "r252", "r253", "r436", "r440", "r517", "r539" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "us-gaap_NetIncomeLoss", "totalLabel": "NET LOSS", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r149", "r150", "r151", "r152", "r157", "r158", "r162", "r165", "r183", "r185", "r188", "r191", "r193" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersOperationsBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss attributable to common stockholders of GB Sciences, Inc. - basic and diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersOperationsBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "auth_ref": [ "r158", "r165" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.", "label": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "negatedTerseLabel": "Continuing operations, basic" } } }, "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": { "auth_ref": [], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.", "label": "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic", "negatedTerseLabel": "Discontinued operations, basic" } } }, "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash investing and financing transactions:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "auth_ref": [ "r125", "r126", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.", "label": "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "terseLabel": "Noncash or Part Noncash Divestiture, Amount of Consideration Received" } } }, "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r101" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 0.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income/(expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "us-gaap_NotesPayableCurrent", "terseLabel": "Notes Payable, Current, Total", "verboseLabel": "Notes and convertible notes payable, net" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r66", "r139", "r469" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent", "terseLabel": "Notes Payable, Related Parties, Current" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r198", "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "us-gaap_NotesReceivableNet", "terseLabel": "Financing Receivable, after Allowance for Credit Loss, Total" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReduction": { "auth_ref": [ "r125", "r126", "r127" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details": { "order": 2.0, "parentTag": "gblx_DeconsolidationEntitysInterestNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.", "label": "Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates", "terseLabel": "Notes Reduction", "verboseLabel": "Extinguishment of debt and accrued interest owed to purchasers of Nevada Subsidiaries and purchasers' affiliates" } } }, "localname": "NotesReduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r183", "r185", "r188", "r191", "r193" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r461", "r463" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r544" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "us-gaap_OtherIncome", "terseLabel": "Other Income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r103" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForBrokerageFees": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for brokerage fees during the current period. This element is intended to represent the brokerage fees paid by and between financial industry participants.", "label": "us-gaap_PaymentsForBrokerageFees", "terseLabel": "Payments for Brokerage Fees" } } }, "localname": "PaymentsForBrokerageFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "us-gaap_PaymentsForLegalSettlements", "terseLabel": "Payments for Legal Settlements" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForPostemploymentBenefits": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflows for payments of postemployment benefits (such as severance pay and health insurance benefits) recognized during the period. Postemployment benefits are benefits paid to employees after employment but before retirement.", "label": "us-gaap_PaymentsForPostemploymentBenefits", "terseLabel": "Payments for Postemployment Benefits" } } }, "localname": "PaymentsForPostemploymentBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r110" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Fees for issuance of convertible notes" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r111" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "us-gaap_PaymentsOfStockIssuanceCosts", "negatedLabel": "Brokerage fees from warrant exercises and stock issuances" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r106" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "us-gaap_PaymentsToAcquireIntangibleAssets", "negatedLabel": "Acquisition of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r65" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets", "terseLabel": "Prepaid and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r108" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible notes payable", "terseLabel": "Proceeds from Convertible Debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries": { "auth_ref": [ "r105" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details": { "order": 1.0, "parentTag": "gblx_DeconsolidationEntitysInterestNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).", "label": "Cash payments received, including advancements of $400,000", "terseLabel": "Proceeds from Divestiture of Interest in Consolidated Subsidiaries", "verboseLabel": "Proceeds from sale of Nevada Subsidiaries" } } }, "localname": "ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "us-gaap_ProceedsFromIssuanceOfPrivatePlacement", "terseLabel": "Proceeds from Issuance of Private Placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r108", "r134" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from line of credit", "terseLabel": "Proceeds from Lines of Credit, Total" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndCollectionOfNotesReceivable": { "auth_ref": [ "r104" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the proceeds from sale of notes receivable, as well as principal collections from a borrowing supported by a written promise to pay an obligation (note receivable).", "label": "Proceeds of note receivable" } } }, "localname": "ProceedsFromSaleAndCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r107" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from warrant exercises", "terseLabel": "Proceeds from Warrant Exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r31", "r84", "r85", "r89", "r113", "r135", "r147", "r155", "r156", "r183", "r185", "r188", "r191", "r193", "r201", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250", "r252", "r253", "r420", "r424", "r425", "r430", "r431", "r436", "r440", "r520" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r226", "r556", "r557", "r558" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r221", "r476", "r521", "r533" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r221", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "auth_ref": [ "r452", "r454" ], "lang": { "en-us": { "role": { "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.", "label": "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate", "terseLabel": "Receivable with Imputed Interest, Effective Yield (Interest Rate)" } } }, "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r330", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r467", "r471" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r330", "r467", "r468", "r471" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r467" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r330", "r467", "r471", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r465", "r466", "r468", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "us-gaap_RepaymentsOfConvertibleDebt", "terseLabel": "Repayments of Convertible Debt" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r109" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "us-gaap_RepaymentsOfRelatedPartyDebt", "negatedLabel": "Principal payment on related party note", "terseLabel": "Repayments of Related Party Debt" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r379", "r487", "r561" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "us-gaap_ResearchAndDevelopmentExpense", "terseLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r53", "r315", "r476", "r531", "r550", "r551" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r144", "r145", "r146", "r148", "r154", "r156", "r202", "r372", "r373", "r374", "r401", "r402", "r434", "r547", "r549" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r131", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r92", "r135", "r179", "r180", "r184", "r189", "r190", "r194", "r195", "r196", "r201", "r241", "r242", "r243", "r246", "r247", "r248", "r249", "r250", "r252", "r253", "r440", "r520" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 }, "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Sales revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "us-gaap_SalariesWagesAndOfficersCompensation", "terseLabel": "Salary and Wage, Excluding Cost of Good and Service Sold, Total" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction", "terseLabel": "Sale of Stock, Consideration Received on Transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.", "label": "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction", "terseLabel": "Sale of Stock, Percentage of Ownership after Transaction" } } }, "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.", "label": "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction", "terseLabel": "Sale of Stock, Percentage of Ownership before Transaction" } } }, "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r4", "r16", "r17", "r18", "r19", "r20", "r21", "r26", "r29", "r30", "r31", "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r40", "r60", "r61", "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in stock options.", "label": "Schedule of Stock Options Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r316", "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentContinuingOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component of an entity expected to operate in the foreseeable future.", "label": "Continuing Operations [Member]" } } }, "localname": "SegmentContinuingOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDiscontinuedOperationsMember": { "auth_ref": [ "r5", "r8", "r9", "r10" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations [Member]" } } }, "localname": "SegmentDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-2-going-concern", "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-2-going-concern", "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r119" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Weighted-average volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, options (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, options (in shares)", "periodStartLabel": "Outstanding, options (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Fully vested and expected to vest, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Fully vested and expected to vest, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Three [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r343", "r362", "r363", "r364", "r365", "r368", "r375", "r378" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r338", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-Based Payment Arrangement, Employee [Member]" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "auth_ref": [ "r336", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-Based Payment Arrangement, Nonemployee [Member]" } } }, "localname": "ShareBasedPaymentArrangementNonemployeeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (in years) (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r46", "r476", "r505", "r528" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Carrying value, short-term notes payable", "terseLabel": "Short-term Debt, Total" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r64", "r509", "r510", "r525" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "us-gaap_ShortTermInvestments", "terseLabel": "Short-Term Investments, Total" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r129", "r143" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r79", "r87", "r88", "r89", "r144", "r145", "r146", "r148", "r154", "r156", "r170", "r202", "r310", "r315", "r372", "r373", "r374", "r401", "r402", "r434", "r442", "r443", "r444", "r445", "r446", "r447", "r464", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-tables", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details-parentheticals", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-tables", "http://gbsciences.com/20220331/role/statement-note-14-concentrations", "http://gbsciences.com/20220331/role/statement-note-14-concentrations-details-textual", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-2-going-concern", "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-tables", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment-details-textual", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-tables", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-tables", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details", "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-2-going-concern", "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r144", "r145", "r146", "r170", "r488" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets", "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-cash-flows", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-", "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-assumptions-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-details-textual", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details", "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-tables", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies", "http://gbsciences.com/20220331/role/statement-note-11-commitments-and-contingencies-details-textual", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions", "http://gbsciences.com/20220331/role/statement-note-12-related-party-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-gain-on-deconsolidation-details-parentheticals", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-tables", "http://gbsciences.com/20220331/role/statement-note-14-concentrations", "http://gbsciences.com/20220331/role/statement-note-14-concentrations-details-textual", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-2-going-concern", "http://gbsciences.com/20220331/role/statement-note-2-going-concern-details-textual", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-discontinued-operations-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-lease-costs-recorded-in-the-companys-financial-statements-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-schedule-of-inventory-details", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-summary-of-notes-and-convertible-notes-payable-details", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-tables", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment", "http://gbsciences.com/20220331/role/statement-note-7-property-and-equipment-details-textual", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-tables", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-tables", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-warrant-activity-details", "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r78", "r275", "r310", "r311", "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Issuance of stock for debt conversion (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r50", "r51", "r310", "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r50", "r51", "r310", "r315", "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercised, options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r79", "r310", "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Issuance of stock for debt conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r51", "r54", "r55", "r135", "r200", "r201", "r440", "r476" ], "calculation": { "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY/(DEFICIT)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY/(DEFICIT):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r88", "r135", "r144", "r145", "r146", "r148", "r154", "r201", "r202", "r315", "r372", "r373", "r374", "r401", "r402", "r417", "r418", "r429", "r434", "r440", "r442", "r443", "r447", "r464", "r548", "r549" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-changes-in-stockholders-equitydeficit-" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r133", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r315", "r317", "r433" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r448", "r478" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r448", "r478" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r448", "r478" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r477", "r479" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations", "http://gbsciences.com/20220331/role/statement-note-1-background-and-nature-of-operations-details-textual", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-details-textual", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events", "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-2-going-concern" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-10-employee-benefit-plan-tables", "http://gbsciences.com/20220331/role/statement-note-13-sale-of-membership-interests-in-nevada-subsidiaries-tables", "http://gbsciences.com/20220331/role/statement-note-4-discontinued-operations-tables", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-tables", "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-tables", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_TaxesPayableCurrent", "terseLabel": "Taxes Payable, Current, Total" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://gbsciences.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit", "http://gbsciences.com/20220331/role/statement-note-5-notes-payable-and-line-of-credit-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r387" ], "calculation": { "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Penalties and interest on prior year tax liabilities" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-8-income-taxes-reconciliation-of-effective-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r171", "r172", "r173", "r174", "r175", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-note-15-subsequent-events-details-textual", "http://gbsciences.com/20220331/role/statement-note-6-convertible-notes-details-textual", "http://gbsciences.com/20220331/role/statement-note-9-capital-transactions-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r157", "r165" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding - basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://gbsciences.com/20220331/role/statement-consolidated-statements-of-operations" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123467568&loc=d3e6835-112609" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "https://asc.fasb.org/topic&trid=2127225" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r34": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r378": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e34017-109320" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121829364&loc=d3e40084-109325" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r432": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r473": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r479": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(17))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r562": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r563": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r564": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r565": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r566": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r567": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r568": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r569": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" } }, "version": "2.1" }